ZYBT Market Analysis

Overview

Fundamentals

P/E ratio
EPS (TTM)$-0.22-79.6% YoY
Profit margin-60.0%HEALTHCARE
Market cap$35.5MMicro cap

Valuation

Forward P/E
PEG ratio
P/B
0.99
P/S (TTM)
0.30
EV/EBITDA
21.76

Profitability & growth

ROE (TTM)
-25.2%
Operating margin
-77.0%
Revenue growth YoY
-40.9%
Dividend yield
Beta
Last earnings
Dec 12, 2025 · Estimate $0.00 · Reported $-0.46
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Zhengye Biotechnology Holding Limited Ordinary Shares

Zhengye Biotechnology Holding Limited (Ticker: ZYBT) is a forward-thinking biotechnology company dedicated to the development and commercialization of cutting-edge biopharmaceutical products. Leveraging proprietary technologies and a promising product pipeline, ZYBT is strategically positioned to meet critical medical needs and improve treatment outcomes across various therapeutic areas. With a strong focus on research and development, the company is committed to driving growth and delivering value to its investors, while upholding high standards of quality and innovation in an increasingly…

Classification

Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
NO.1 LIANMENG ROAD, JILIN, CHINA
Fiscal year end
December
Latest quarter
Dec 31, 2025
Market cap$35.5M
Shares outstanding$47.4M
52W high$13.08
52W low$0.68

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer